Scopio Labs

Scopio Labs develops platforms that combine computational photography with AI to offer full-field digital imaging and analysis of blood and bone marrow samples. This technology addresses the long-standing trade-off between a wide field of view and high resolution in microscopy, allowing lab professionals to view the entire sample area at 100X magnification. The company’s products include the Scopio X100 and the high-throughput X100HT platforms. These systems feature applications like the Full-Field Peripheral Blood Smear (FF-PBS), which automates the analysis of white and red blood cells and provides platelet estimates. Another key offering is the Full-Field Bone Marrow Aspirate™ (FF-BMA) application, the first of its kind to receive De Novo clearance from the U.S. Food and Drug Administration (FDA), establishing a new regulatory category for digital BMA analysis.

The company serves hospitals and hematology laboratories, aiming to improve diagnostic efficiency and accuracy. Its platforms streamline laboratory workflows, reduce turnaround times by up to 60%, and enable remote analysis and collaboration among specialists through secure hospital networks. The business model involves the sale of these digital microscopy systems and their accompanying software applications. The company has forged strategic partnerships for global distribution, including with Siemens Healthineers and Beckman Coulter. Scopio Labs has secured significant funding, with a total of over $125 million raised across multiple rounds from investors such as Fortissimo Capital, OurCrowd, and Viola Growth.